Olugbenga obtained his Bachelor of Laws degree (LLB, First Class Honours) from the University of Ibadan, Nigeria in 2007. He was called to the Nigerian Bar as a Barrister and Solicitor of the Supreme Court of Nigeria in 2008.
In 2009, Olugbenga was awarded a Commonwealth Scholarship by the Cambridge Trust to study LLM in International Law at the Faculty of Law, University of Cambridge.
In 2011, Olugbenga worked briefly as an attorney with the law firm of Wahab Egbewole & Co. and was later employed as a lecturer at the Department of Business Law, Faculty of Law, University of Ilorin. He has teaching experience in Contract Law, Law of Intellectual Property, Company Law, and Introduction to Business Law.
In 2012, Olugbenga was awarded the WIPO/ARIPO/AU scholarship to study for another Master degree known as Master in Intellectual Property (MIP) at the Institute of Peace, Leadership and Governance (IPLG), Africa University, Zimbabwe. He was awarded the WIPO/ARIPO/AU prize for the best graduating student for the 2013 graduating set.
Olugbenga joined the CLG and the Faculty of Law, UTAS in December 2016 as a PhD student to examine how the East African Community can deploy TRIPS flexibilities to boost local manufacturing capacity and improve access to essential medicines in their community.
Using TRIPS Flexibilities to Build Regional Pharmaceutical Manufacturing Capacity and Improve Access to Essential Medicines in the East African Community
With the current wide gap existing between people who require access to essential medicines and people who actually have access to essential medicines in the East African Community (EAC), the research seeks to probe into how the EAC can harness the flexibilities available to it under the WTO-TRIPS Agreement to boost local pharmaceutical manufacturing capacity and improve access to essential medicines for its population.
Relevant questions that will be examined in the course of the research are: whether the current global IP regime of higher protection for pharmaceutical patents can influence the issue of access to essential medicines in this region one way or the other; whether the current EAC Policy on the Utilisation of Public Health-Related WTO-TRIPS Flexibilities and Approximation of National Intellectual Property Legislation is couched in a manner that will allow partner states and the region to take full benefits of these flexibilities for boosting access to essential medicines; whether there is a policy and/or legal coherence between the IP laws of the partner states and the regional policies on flexibilities; whether the EAC Regional Pharmaceutical Manufacturing Plan of Action (2012-2016) has achieved its core aim of improving access to essential medicines through local production in the region; and finally, whether the region can successfully reconcile its access to essential medicines quest with the need to deal with counterfeit medicines, especially in the face of the recent proliferation of anti-counterfeiting laws by some of its partner states.
At the end, the research intends to recommend necessary legal and policy interventions that may assist the region to achieve an improved access to essential medicines for its population.
Research focus areas
Intellectual Property, Access to medicines, International trade, Law of Contract, Company Law
No results were found